The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial.
The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial.
复制标题
DOI：
10.1177/1099800410397629
复制
发表时间：
2012-01
影响因子：
2.5
通讯作者：
Barrett TA
中科院分区：
文献类型：
--
作者：
Keefer L;Kiebles JL;Kwiatek MA;Palsson O;Taft TH;Martinovich Z;Barrett TA
Inflammatory bowel diseases (IBD) are chronic inflammatory illnesses marked by unpredictable disease flares, which occur spontaneously and/or in response to external triggers, especially personal health behaviors. Behavioral triggers of flare may be responsive to disease self-management programs. We report on interim findings of a randomized controlled trial of gut-directed hypnotherapy (HYP, n = 19) versus active attention control (CON, n = 17) for quiescent ulcerative colitis (UC). To date, 43 participants have enrolled; after 5 discontinuations (1 in HYP) and 2 exclusions due to excessive missing data, 36 were included in this preliminary analysis. Aim 1 was to determine the feasibility and acceptability of HYP in UC. This was achieved, demonstrated by a reasonable recruitment rate at our outpatient tertiary care clinic (20%), high retention rate (88% total), and our representative IBD sample, which is reflected by an equal distribution of gender, an age range between 21 and 69, recruitment of ethnic minorities (~20%), and disease duration ranging from 1.5 to 35 years. Aim 2 was to estimate effect sizes on key clinical outcomes for use in future trials. Effect sizes (group × time at 20 weeks) were small to medium for IBD self-efficacy (.34), Inflammatory Bowel Disease Questionnaire (IBDQ) total score (.41), IBDQ bowel (.50), and systemic health (.48). Between-group effects were observed for the IBDQ bowel health subscale (HYP > CON; p = .05) at 20 weeks and the Short Form 12 Health Survey Version 2 (SF-12v2) physical component (HYP > CON; p < .05) at posttreatment and 20 weeks. This study supports future clinical trials testing gut-directed HYP as a relapse prevention tool for IBD.
登录
查看更多内容
DOI：
10.1097/00005176-199904001-00003
发表时间：
1999-04-01
影响因子：
2.9
作者：
Irvine, EJ
通讯作者：
Irvine, EJ
影响因子：
9.8
作者：
Levenstein, S;Prantera, C;Marcheggiano, A
通讯作者：
Marcheggiano, A
影响因子：
4.9
作者：
Bernstein, Charles N.;Fried, Michael;Watermeyer, Gillian
通讯作者：
Watermeyer, Gillian
影响因子：
3
作者：
KAZIS, LE;ANDERSON, JJ;MEENAN, RF
通讯作者：
MEENAN, RF
影响因子：
4.7
作者：
LEVENSTEIN, S;PRANTERA, C;ANDREOLI, A
通讯作者：
ANDREOLI, A